Retatrutide

Triple Targeting: It can simultaneously activate glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic peptide receptor (GIPR), and glucagon receptor (GCGR). Significant Weight Loss: Clinical trials (such as the Phase 3 TRIUMPH program) have shown breakthrough weight loss effects, with the highest dose group achieving an average weight loss of over 24% to 30% after prolonged treatment. Comprehensive Metabolic Improvement: In addition to weight loss and blood sugar reduction, it can significantly reduce liver fat content and improve some obesity-related complications.